rapidli
emerg
infecti
diseas
outbreak
place
great
strain
laboratori
develop
implement
sensit
specif
diagnost
test
patient
manag
infect
control
time
manner
furthermor
laboratori
also
play
role
realtim
zoonot
environment
epidemiolog
investig
identifi
ultim
sourc
epidem
facilit
measur
eventu
control
outbreak
assay
modal
uniqu
pro
con
therefor
incorpor
batteri
test
use
tradit
culturebas
molecular
serolog
diagnost
diagnost
algorithm
often
requir
laboratori
face
challeng
assay
develop
test
evalu
subsequ
qualiti
assur
review
describ
differ
test
modal
avail
ongo
middl
east
respiratori
syndrom
mer
epidem
includ
cell
cultur
nucleic
acid
amplif
antigen
detect
antibodi
detect
assay
applic
test
acut
clinic
epidemiolog
investig
set
highlight
use
mer
epidem
exampl
illustr
variou
challeng
face
laboratori
test
develop
implement
set
rapidli
emerg
infecti
diseas
futur
direct
diagnosi
mer
emerg
infecti
diseas
investig
also
highlight
ongo
threat
emerg
viral
infect
global
public
health
well
evidenc
recent
epidem
caus
middl
east
respiratori
syndrom
coronaviru
merscov
avian
influenza
virus
ebola
viru
zika
viru
et
al
chan
et
al
chan
et
al
prompt
accur
diagnosi
first
step
success
control
epidem
particularli
import
emerg
viral
infect
may
spread
rapidli
may
associ
sever
complic
sridhar
et
al
definit
diagnosi
emerg
viral
infect
usual
requir
laboratori
confirm
clinic
featur
epidemiolog
risk
factor
may
similar
relat
infect
characterist
ideal
laboratori
assay
diagnos
infect
includ
high
sensit
high
specif
short
turnaround
time
low
cost
low
expertis
facil
requir
suitabl
use
differ
specimen
type
avail
pointofcar
test
poct
capabl
quantifi
viral
load
unfortun
despit
recent
advanc
field
singl
laboratori
diagnost
test
characterist
therefor
import
understand
clinic
applic
variou
type
laboratori
diagnost
assay
role
control
emerg
viral
epidem
review
use
mer
epidem
exampl
illustr
advantag
disadvantag
practic
use
impact
epidem
control
major
type
laboratori
diagnost
assay
avail
emerg
viral
infect
middl
east
respiratori
syndrom
coronaviru
merscov
novel
lineag
c
betacoronaviru
first
isol
saudi
arabian
man
sever
acut
communityacquir
pneumonia
acut
kidney
injuri
zaki
et
al
decemb
case
human
mer
case
includ
fatal
report
world
health
organ
http
whointemergenciesmerscov
en
epidem
continu
expand
sinc
human
case
mer
report
middl
east
result
animaltohuman
transmiss
infect
anim
reservoir
dromedari
camel
possibl
bat
region
persontoperson
transmiss
healthcareassoci
outbreak
reusken
et
al
haagman
et
al
wang
et
al
chan
et
al
moreov
sporad
case
cluster
human
mer
infect
also
occur
area
import
case
mer
republ
korea
clinic
present
mer
may
rang
asymptomat
infect
detect
contact
trace
outbreak
investig
rapidli
fatal
diseas
chan
et
al
diseas
especi
sever
elderli
men
comorbid
assiri
et
al
sever
mer
character
rapidli
progress
acut
pneumonia
fever
respiratori
failur
respons
broadspectrum
antibacteri
treatment
may
associ
extrapulmonari
manifest
includ
acut
kidney
injuri
hepat
dysfunct
gastrointestin
symptom
seizur
chan
et
al
chan
et
al
zaki
et
al
assiri
et
al
arabi
et
al
number
repurpos
drug
antivir
peptid
monoclon
antibodi
demonstr
antimerscov
activ
vitro
andor
anim
model
none
proven
effect
random
control
trial
yet
chan
et
al
chan
et
al
gao
et
al
lu
et
al
jiang
et
al
tang
et
al
ying
et
al
variou
vaccin
develop
undergo
clinic
trial
andor
test
camel
uyeki
et
al
like
infecti
diseas
appropri
specimen
collect
import
step
laboratori
diagnosi
mer
requir
knowledg
viral
kinet
variou
specimen
type
relat
time
sinc
symptom
onset
like
sarscov
merscov
viral
load
respiratori
specimen
peak
second
week
symptom
onset
oh
et
al
therefor
patient
test
neg
mer
soon
symptom
onset
undergo
repeat
test
epidemiolog
histori
suggest
mer
lower
respiratori
tract
specimen
includ
tracheal
aspir
bronchoalveolar
lavag
fluid
well
collect
sputum
specimen
contain
highest
viral
rna
load
collect
whenev
possibl
corman
et
al
oh
et
al
howev
invas
procedur
obtain
lower
respiratori
specimen
may
alway
feasibl
especi
patient
mild
ill
upper
respiratori
tract
specimen
nasopharyng
swab
oropharyng
swab
andor
nasopharyng
aspir
taken
case
pool
swab
singl
contain
maxim
rna
load
viral
load
upper
respiratori
tract
consist
lower
lower
respiratori
tract
memish
et
al
corman
et
al
risk
assess
regard
requisit
transmissionbas
precaut
patient
placement
person
protect
equip
specimen
collect
conduct
due
possibl
aerosol
gener
specimen
sent
laboratori
viral
transport
medium
contain
balanc
salt
solut
bovin
serum
albumin
ph
buffer
phenol
red
antimicrobi
soon
possibl
specimen
process
like
delay
storag
ultralow
freezer
recommend
extrapulmonari
specimen
report
contain
detect
merscov
rna
includ
blood
stool
urin
drosten
et
al
poissi
et
al
corman
et
al
specimen
may
provid
opportun
mer
diagnosi
lower
respiratori
tract
specimen
unavail
howev
viral
load
specimen
type
gener
lower
lower
respiratori
tract
although
report
except
abroug
et
al
detect
merscov
stool
specimen
may
infect
control
implic
detect
merscov
rna
whole
blood
serum
particular
may
prognost
marker
poor
outcom
gueri
et
al
kim
et
al
serolog
test
acut
convalesc
serum
specimen
ideal
collect
day
apart
enabl
document
seroconvers
rise
neutral
antibodi
titer
serum
specimen
acut
phase
avail
convalesc
phase
serum
specimen
may
also
use
establish
retrospect
diagnosi
panel
antibodi
test
see
serolog
section
choic
investig
depend
specimen
type
time
postsymptom
onset
local
test
avail
advantag
shortcom
differ
test
detail
summar
tabl
isol
infecti
merscov
cell
cultur
inocul
patient
bodili
fluid
andor
tissu
establish
diagnosi
mer
zaki
et
al
although
routin
use
viral
cultur
diagnos
mer
standard
clinic
microbiolog
laboratori
limit
method
rel
slower
turnaround
time
molecular
diagnost
requir
biosafeti
level
facil
timetest
diagnost
tool
play
import
role
discoveri
studi
pathogenesi
antivir
merscov
unlik
humanpathogen
cov
notori
difficult
cultur
cell
line
merscov
replic
rapidli
induct
promin
cytopath
effect
broad
rang
cell
line
muller
et
al
chan
et
al
merscov
produc
focal
cytopath
effect
round
refractil
cell
suscept
cell
line
within
day
inocul
primari
isol
chan
et
al
spread
chang
throughout
cell
monolay
lead
round
detach
cell
within
day
syncytium
format
caus
fusion
activ
merscov
spike
protein
may
seen
cell
line
zaki
et
al
chan
et
al
de
wild
et
al
rapid
promin
cytopath
effect
allow
zaki
colleagu
success
isol
first
merscov
strain
cell
line
commonli
use
clinic
virolog
laboratori
vero
shortli
inocul
index
patient
sputum
sampl
cell
line
zaki
et
al
recent
comparison
vero
cell
line
isol
merscov
show
isol
rate
merscov
significantli
higher
vero
cell
vs
p
muth
et
al
isol
rate
merscov
cell
cultur
higher
respiratori
sampl
higher
viral
rna
load
vs
sampl
copiesml
copiesml
respect
lower
respiratori
tract
sampl
nasopharyng
aspir
sputa
endotrach
aspir
sampl
collect
earlier
diagnosi
vs
sampl
collect
within
day
diagnosi
respect
factor
consid
laboratori
attempt
isol
merscov
clinic
specimen
broad
tissu
tropism
merscov
cell
line
differ
human
organ
tissu
origin
corrobor
protean
clinic
manifest
mer
human
high
viral
load
merscov
human
lung
kidney
colon
hepat
cell
line
correl
predominantli
lower
respiratori
tract
involv
extrapulmonari
manifest
acut
kidney
injuri
diarrhea
hepat
dysfunct
respect
chan
et
al
vitro
observ
subsequ
valid
ex
vivo
organ
tissu
cultur
andor
anim
model
chan
et
al
zhou
et
al
chu
et
al
yeung
et
al
replic
merscov
monocyt
dendrit
cell
lymphocyt
aberr
induct
inflammatori
cytokineschemokin
activ
extrins
intrins
apoptosi
pathway
partli
explain
pathogenesi
viru
dissemin
cytokinechemokin
storm
lymphopenia
sever
mer
lau
et
al
chu
et
al
chu
et
al
zhou
et
al
zhou
et
al
scheuplein
et
al
tynel
et
al
moreov
merscov
could
isol
numer
nonhuman
cell
line
includ
nonhuman
primat
camel
bat
origin
muller
et
al
chan
et
al
eckerl
et
al
contrast
cell
line
mous
rat
origin
suscept
chan
et
al
vitro
biolog
characterist
merscov
provid
insight
possibl
clinic
manifest
anim
reservoir
anim
speci
suscept
merscov
infect
anim
model
develop
earli
stage
epidem
de
wit
et
al
munster
et
al
coleman
et
al
falzarano
et
al
yao
et
al
zhao
et
al
agraw
et
al
chan
et
al
haagman
et
al
viral
cultur
merscov
also
facilit
identif
evalu
antimerscov
drug
screen
potenti
candid
antimerscov
agent
chemic
librari
consist
larg
number
clinic
approv
drug
valid
vitro
antimerscov
activ
cytopath
effect
inhibit
viral
load
reduct
plaqu
reduct
assay
use
cell
cultur
system
success
identifi
repurpos
drug
type
interferon
lopinavirritonavir
test
anim
model
chan
et
al
dyall
et
al
de
wild
et
al
similarli
antimerscov
effect
newli
design
antivir
peptid
monoclon
antibodi
also
valid
cell
cultur
gao
et
al
jiang
et
al
lu
et
al
tang
et
al
ying
et
al
avail
viral
cultur
merscov
refer
research
laboratori
crucial
deepen
understand
find
countermeasur
mer
given
limit
viral
cultur
rapid
readili
avail
laboratori
assay
requir
diagnos
mer
specif
primer
standard
laboratori
protocol
quickli
develop
success
isol
first
merscov
strain
sequenc
complet
genom
earli
epidem
septemb
palm
et
al
posit
sens
singlestrand
rna
genom
merscov
size
approxim
kb
arrang
order
open
read
frame
orf
structur
protein
senvelop
e
membran
nucleocapsid
n
poli
woo
et
al
chan
et
al
lau
et
al
number
monoplex
revers
transcriptionpolymeras
chain
reaction
rtpcr
assay
use
primer
target
conserv
gene
region
merscov
genom
develop
evalu
screen
andor
confirmatori
test
gene
target
includ
leader
sequenc
region
rnadepend
rna
polymeras
rdrp
upe
upstream
envelop
e
gene
n
gene
region
corman
et
al
corman
et
al
lu
et
al
chan
et
al
dougla
et
al
commonli
adopt
diagnost
protocol
util
upe
assay
screen
test
follow
either
assay
confirm
gener
assay
highli
sensit
specif
technic
limit
detect
rang
rna
copiesreact
chan
et
al
kim
et
al
limit
detect
appear
lowest
assay
target
abundantli
express
leader
sequenc
region
n
gene
although
clinic
comparison
among
variou
assay
report
assay
evalu
use
clinic
specimen
includ
respiratori
nasopharyng
aspir
sputum
endotrach
aspir
bronchoalveolar
lavag
fluid
andor
nose
mouth
exud
andor
extrapulmonari
specimen
serum
urin
andor
stool
number
region
intern
extern
qualiti
assess
show
major
particip
laboratori
capabl
detect
merscov
rna
rtpcr
assay
high
accuraci
falseneg
result
might
occur
minor
sampl
low
viral
load
pa
et
al
seong
et
al
zhang
et
al
recent
advanc
molecular
diagnost
mer
includ
develop
commerci
monoplex
multiplex
rtpcr
kit
novel
nonpcrbas
diagnost
commerci
assay
util
primer
target
upe
andor
gene
region
kim
et
al
http
wwwfasttrackdiagnost
comproductsftdmerscov
http
engbioneercomdiagnostichumanmdxkitsaccupowermerscovmultiplexoverviewaspx
http
seegenecomneoenproductsrespiratoryanyplexmerscovphp
intern
control
assay
includ
primer
human
glyceraldehyd
dehydrogenas
gene
housekeep
gene
found
clinic
specimen
spike
rna
tobacco
mosaic
viru
dna
phocin
herpesviru
dna
spike
pcr
mixtur
analyt
clinic
evalu
assay
show
gener
high
sensit
specif
falseneg
invalid
result
may
occur
specimen
contain
high
level
pcr
inhibitor
sputum
specimen
kim
et
al
sputum
homogen
prior
nucleic
acid
extract
proteinas
k
dnase
treatment
may
effect
either
phosphatebuff
salin
treatment
nacetyllcystein
sodium
citrat
treatment
improv
sensit
assay
perform
multiplex
assay
may
improv
use
selfavoid
molecular
recognit
systemartifici
expand
genet
inform
system
samrsaegi
primer
reduc
nonspecif
reaction
gener
among
multipl
primer
assay
glushakova
et
al
yaren
et
al
main
advantag
commerci
diagnost
kit
eas
use
laboratori
without
technic
expertis
design
perform
inhousedevelop
rtpcr
assay
major
disadvantag
rel
high
cost
may
limit
use
resourcelimit
region
nonpcrbas
assay
mer
includ
revers
transcriptionloopmedi
isotherm
amplif
rtlamp
revers
transcript
isotherm
recombinas
polymeras
amplif
rtrpa
abd
el
wahe
et
al
shirato
et
al
bhadra
et
al
isotherm
assay
gener
short
incub
time
highli
sensit
specif
simpl
perform
requir
thermocycl
therefor
especi
suitabl
poct
resourcelimit
area
expertis
equip
rtpcr
readili
avail
addit
establish
diagnosi
nucleic
acid
amplif
test
appli
fulfil
number
import
purpos
mer
epidem
firstli
use
investig
anim
reservoir
merscov
establish
link
dromedari
camel
human
case
mer
haagman
et
al
lau
et
al
higher
rate
detect
merscov
rna
nasal
andor
rectal
swab
juvenil
camel
adult
camel
help
identifi
juvenil
camel
import
sourc
cameltohuman
transmiss
mer
alagaili
et
al
werneri
et
al
secondli
rtpcr
commonli
employ
contact
trace
healthcareassoci
outbreak
mer
assiri
et
al
memish
et
al
drosten
et
al
oboho
et
al
outbreak
investig
recogn
asymptomat
infect
might
occur
young
previous
healthi
person
might
serv
sourc
persontoperson
transmiss
mer
memish
et
al
omrani
et
al
thirdli
serial
test
differ
clinic
sampl
mer
patient
rtpcr
identifi
shed
pattern
viru
respiratori
nonrespiratori
sampl
notabl
viral
rna
detect
stool
urin
sampl
suggest
clinic
sampl
may
also
import
spread
mer
fourthli
viral
rna
load
found
predict
factor
sever
diseas
high
merscov
load
lower
respiratori
tract
specimen
predict
progress
pneumonia
blood
merscov
rna
posit
initi
diagnosi
associ
wors
clinic
outcom
term
higher
rate
requir
mechan
ventil
extracorpor
membran
oxygen
well
death
p
fifthli
rtpcr
commonli
employ
vitro
vivo
antivir
vaccin
evalu
studi
zumla
et
al
final
rtpcr
sequenc
import
survey
molecular
epidemiolog
chang
may
associ
viru
adapt
effici
persontoperson
transmiss
molecular
diagnost
assay
excel
sensit
diagnosi
merscov
infect
howev
assay
requir
dedic
facil
expens
equip
highli
train
personnel
place
great
strain
laboratori
infrastructur
endem
area
mer
therefor
consider
interest
develop
merscov
antigen
detect
assay
better
pcr
diagnosi
term
conveni
specif
monoclon
antibodi
target
merscov
protein
use
demonstr
evid
merscov
infect
tissu
de
wit
et
al
antibodi
also
use
detect
merscov
n
protein
respiratori
specimen
antigen
abundantli
express
acut
phase
ill
four
assay
detect
merscov
n
protein
describ
date
song
et
al
yamaoka
et
al
peptid
use
immun
mice
rais
monoclon
antibodi
either
form
recombin
protein
synthet
produc
clone
correspond
dna
fragment
e
coli
subsequ
purifi
protein
prepar
use
wheat
germ
extractbas
cell
free
express
system
research
either
use
singl
long
peptid
pool
smaller
synthet
peptid
span
length
merscov
n
protein
song
et
al
yamaoka
et
al
monoclon
antibodi
produc
favor
signaltonois
ratio
recombin
merscov
n
protein
immunoassay
select
incorpor
either
enzymelink
immunosorb
assay
elisa
yamaoka
et
al
poct
format
chen
et
al
analyt
sensit
antigen
detect
assay
measur
use
lower
limitofdetect
lod
experi
previous
describ
elisa
assay
lod
ml
use
simul
npa
specimen
seed
serial
dilut
merscov
cultur
later
flow
immunoassay
lfia
also
describ
us
lod
least
merscov
immunochromatograph
test
ict
develop
song
et
al
lod
ngml
recombin
merscov
n
protein
elisa
assay
develop
yamaoka
et
al
could
detect
ngml
n
protein
yamaoka
et
al
due
care
select
monoclon
antibodi
publish
assay
quit
specif
merscov
crossreact
anim
human
coronavirus
main
advantag
antigen
detect
assay
eas
use
rapid
result
especi
adapt
poct
format
poct
perform
entir
within
biosafeti
cabinet
builtin
qualiti
control
requir
minim
train
laboratori
personnel
offer
rapid
specif
rulein
option
clinician
pend
pcr
test
may
requir
send
refer
laboratori
long
turnaround
time
region
laboratori
infrastructur
well
develop
howev
sever
obstacl
applic
antigen
detect
diagnosi
mer
human
firstli
assay
valid
clinic
specimen
suspect
mer
case
endem
area
headtohead
comparison
pcr
commonli
employ
platinum
standard
diagnost
method
mer
patient
experi
respiratori
virus
sensit
expect
lower
pcr
test
may
provid
fals
reassur
laps
infect
control
fals
neg
result
interpret
without
confirmatori
pcr
assay
chan
et
al
furthermor
antigen
detect
poct
elisa
design
date
evalu
use
nasopharyng
specimen
unknown
whether
assay
use
lower
respiratori
tract
specimen
often
observ
contain
higher
viral
load
npa
drosten
et
al
gueri
et
al
would
theoret
even
suitabl
antigen
detect
assay
lastli
antigen
detect
assay
featur
cdc
algorithm
diagnosi
mer
limit
interest
develop
commerci
kit
stage
http
wwwcdcgovcoronavirusmerslablabtestinghtml
http
antigen
detect
assay
may
potenti
role
epidemiolog
surveil
camel
ict
develop
song
et
al
valid
use
camel
nasal
swab
demonstr
high
sensit
specif
compar
upe
real
time
rtpcr
lfia
also
show
moder
high
sensit
excel
specif
compar
real
time
rtpcr
dromedari
camel
respiratori
specimen
studi
indic
assay
use
conveni
detect
infect
camel
rural
endem
area
data
regard
kinet
antibodi
respons
mer
patient
steadili
accumul
appear
consider
persontoperson
variat
robust
time
antibodi
respons
viral
infect
initi
igm
respons
follow
rise
igg
titer
usual
detect
week
symptom
onset
drosten
et
al
chan
et
al
park
et
al
longitudin
serolog
one
mersinfect
patient
china
show
anti
elisa
antibodi
rose
antin
antibodi
wang
et
al
differenti
kinet
antin
anti
antibodi
set
mer
serodiagnosi
requir
studi
antibodi
remain
detect
long
clearanc
infect
neutral
antibodi
persist
detect
patient
month
jordanian
mer
outbreak
payn
et
al
wide
varieti
serolog
assay
describ
detect
merscovspecif
antibodi
variat
assay
format
antigen
use
antibodi
subtyp
detect
mer
specif
igm
detect
featur
diagnost
algorithm
promulg
us
cdc
http
wwwcdcgovcoronavirusmerslablabtestinghtml
http
although
igm
titer
theoret
rise
igg
experi
sera
sar
mer
patient
suggest
time
lag
two
may
short
much
clinic
valu
woo
et
al
meyer
et
al
wang
et
al
furthermor
igm
assay
potenti
prone
nonspecif
posit
crossreact
coronavirus
requir
te
diou
specimen
prepar
qualiti
control
buchholz
et
al
addit
valu
test
merscov
igm
patient
present
acut
ill
requir
elucid
view
factor
serolog
assay
describ
mer
diagnosi
either
aim
detect
total
immunoglobulin
igg
major
variabl
serolog
assay
merscov
sourc
antigen
refer
research
laboratori
cell
cultur
facil
merscovinfect
cell
conveni
sourc
antigen
cell
lysat
may
spot
glass
slide
microtit
plate
western
blot
strip
downstream
serolog
assay
although
conveni
assay
requir
reliabl
mean
inactiv
live
viru
within
cultur
extract
furthermor
assay
also
shown
cross
react
coronavirus
infect
cell
express
wide
rang
viral
antigen
like
conserv
across
differ
coronaviru
subgroup
even
genera
aburizaiza
et
al
sar
shown
western
blot
whole
viru
lysat
may
enabl
us
differenti
genuin
seropattern
falseposit
howev
tediou
procedur
requir
technic
expertis
well
character
control
sera
view
shortcom
recombin
antigen
use
elisa
immunofluoresc
ifa
western
blot
protein
microarray
even
pseudoparticl
neutral
assay
corman
et
al
perera
et
al
reusken
et
al
chan
et
al
park
et
al
wang
et
al
use
recombin
antigen
two
major
advantag
firstli
biosafeti
assay
product
major
concern
secondli
method
enabl
select
immunogen
merscovspecif
antigen
maxim
assay
specif
sensit
viral
n
protein
abundantli
express
immunogen
antigen
stimul
antibodi
product
meyer
et
al
sar
patient
evid
antin
antibodi
rise
anti
antibodi
woo
et
al
howev
convalesc
sera
tend
react
antigen
moder
high
sensit
differ
two
antigen
lie
specif
although
n
protein
easier
clone
purifi
smaller
fewer
glycosyl
site
conserv
within
coronaviru
subgroup
compar
protein
major
target
neutral
antibodi
meyer
et
al
therefor
recombin
merscov
n
proteinbas
serolog
assay
expect
higher
rate
cross
reactiv
compar
anti
detect
assay
inde
n
epitop
cross
reactiv
may
even
extend
across
coronaviru
genera
sarscov
n
proteinbas
elisa
show
propens
produc
fals
posit
result
test
convalesc
sera
patient
recov
even
infect
woo
et
al
howev
evid
suggest
even
section
subunit
protein
induc
crossreact
antibodi
differ
betacoronavirus
chan
et
al
studi
requir
elucid
optim
specif
recombin
antigen
mer
serolog
test
mani
classic
serolog
assay
format
appli
mer
modif
interest
assay
specif
biosafeti
principl
advantag
disadvantag
assay
type
summar
tabl
commerci
igg
elisa
assay
avail
provid
fast
sensit
screen
tool
posit
result
elisa
requir
confirm
specif
assay
either
ifa
goldstandard
neutral
assay
detail
evalu
mani
publish
assay
possibl
lack
wellcharacter
control
sera
specif
assay
assess
use
sera
patient
nonendem
region
diagnost
sensit
comparisonofmethod
data
still
difficult
come
recent
studi
park
et
al
compar
plaqu
reduct
neutral
test
prnt
microneutr
pseudoparticl
neutral
test
use
sera
patient
south
korean
mer
outbreak
park
et
al
found
differ
neutral
test
format
excel
correl
test
convalesc
clinic
specimen
first
ten
day
symptom
onset
antim
antibodi
usual
undetect
irrespect
assay
format
park
et
al
park
et
al
therefor
serolog
test
use
acut
mer
although
includ
seroconvers
confirm
neutral
pair
sera
taken
least
day
apart
one
diagnost
criteria
confirm
case
http
role
mer
serolog
therefor
threefold
firstli
provision
diagnos
mild
asymptomat
mer
case
present
late
convalesc
sera
avail
secondli
serosurveil
atrisk
individu
either
part
outbreak
investig
abattoir
exposur
zoonot
sourc
may
occur
muller
et
al
kim
et
al
thirdli
seroepidemiolog
studi
zoonot
sourc
identifi
affect
camel
herd
inde
demonstr
merscov
neutral
antibodi
camel
sera
one
line
evid
zoonot
transmiss
mer
camel
human
meyer
et
al
view
defici
serolog
assay
outlin
tabl
author
recommend
use
least
two
differ
assay
specif
serodiagnosi
mer
recommend
use
either
elisaor
ifabas
screen
assay
follow
confirmatori
test
posit
sera
use
specif
neutral
assay
http
cdc
also
adopt
twophas
approach
first
test
igg
elisa
follow
confirmatori
test
use
ifa
http
wwwcdcgovcoronavirusmerslablabtestinghtml
microneutr
perform
elisaposit
ifaindetermin
sera
final
resolut
experi
mer
recent
transnat
epidem
prove
emerg
infecti
diseas
continu
major
challeng
futur
rise
human
popul
forc
anim
human
ever
closer
proxim
increas
risk
zoonot
transmiss
novel
infecti
diseas
overcrowd
facilit
humantohuman
transmiss
infect
commun
healthcar
set
high
volum
air
travel
enabl
rapid
transport
infect
human
nonendem
region
lead
major
outbreak
featur
clearli
illustr
recent
mer
epidem
key
combat
threat
inform
share
constant
vigil
effici
infect
control
diagnost
laboratori
play
increasingli
import
role
earli
detect
infect
patient
enabl
prompt
initi
infect
control
measur
appropri
patient
manag
howev
role
complex
one
requir
batteri
test
diagnost
algorithm
highlight
review
laboratori
also
face
sever
challeng
role
relat
assay
valid
reagent
shortag
lack
standard
materi
protocol
standard
qualiti
assur
creation
region
global
laboratori
network
aegi
organ
crucial
overcom
difficulti
pool
posit
control
materi
serolog
molecular
assay
biobank
would
also
valuabl
particularli
import
increas
introduct
massiv
multiplex
pointofcar
test
diagnosi
emerg
infect
emerg
trend
microbiolog
laboratori
